Cholinergic Drugs for Alzheimer's Disease: From Central Cholinergic Neurotransmission to Drug Therapies and Natural Products with Multitarget Actions addresses the urgent need for advanced resources in neuropharmacology. The first section presents mechanistic insights into cholinergic drugs, current hypotheses for Alzheimer's Disease progression, neurotransmitter systems, receptor biology, and the evolution of acetylcholinesterase inhibitors, including hybrid and multi-target drugs. It also covers clinical status, neuromuscular blockers, non-adrenergic neurotransmitters, protein kinase inhibitors, inflammation modulation, NMDA antagonism, biomarkers, and AI-assisted drug discovery.The second section explores natural alkaloidal and non-alkaloidal compounds, molecular docking, SAR analysis, and daily consumable resources, with the third section investigating marine-derived AChE inhibitors, dual- and multi-target drug concepts, and emerging therapeutic compounds. This book equips the scientific community with a robust foundation for understanding and innovating in Alzheimer's Disease therapy. By integrating molecular biology, pharmacology, and computational approaches, it empowers researchers and clinicians to address treatment challenges, optimize drug design, and leverage natural products for multifactorial intervention. - Explores cholinesterase inhibitors for cognitive improvement- Summarizes receptor mechanisms in cholinergic transmission- Reviews marine and plant-derived AChE inhibitors for innovative treatments- Presents emerging drug therapies and multitarget natural compounds for Alzheimer's Disease

Cholinergic Drugs for Alzheimer's Disease: From Central Cholinergic Neurotransmission to Drug Therapies and Natural Products with Multitarget Actions addresses the urgent need for advanced resources in neuropharmacology. The first section presents mechanistic insights into cholinergic drugs, current hypotheses for Alzheimer's Disease progression, neurotransmitter systems, receptor biology, and the evolution of acetylcholinesterase inhibitors, including hybrid and multi-target drugs. It also covers clinical status, neuromuscular blockers, non-adrenergic neurotransmitters, protein kinase inhibitors, inflammation modulation, NMDA antagonism, biomarkers, and AI-assisted drug discovery.The second section explores natural alkaloidal and non-alkaloidal compounds, molecular docking, SAR analysis, and daily consumable resources, with the third section investigating marine-derived AChE inhibitors, dual- and multi-target drug concepts, and emerging therapeutic compounds. This book equips the scientific community with a robust foundation for understanding and innovating in Alzheimer's Disease therapy. By integrating molecular biology, pharmacology, and computational approaches, it empowers researchers and clinicians to address treatment challenges, optimize drug design, and leverage natural products for multifactorial intervention. - Explores cholinesterase inhibitors for cognitive improvement- Summarizes receptor mechanisms in cholinergic transmission- Reviews marine and plant-derived AChE inhibitors for innovative treatments- Presents emerging drug therapies and multitarget natural compounds for Alzheimer's Disease

Cholinergic Drugs for Alzheimer's Disease: From Central Cholinergic Neurotransmission to Drug Therapies and Natural Products with Multitarget Actions addresses the urgent need for advanced resources in neuropharmacology. The first section presents mechanistic insights into cholinergic drugs, current hypotheses for Alzheimer's Disease progression, neurotransmitter systems, receptor biology, and the evolution of acetylcholinesterase inhibitors, including hybrid and multi-target drugs. It also covers clinical status, neuromuscular blockers, non-adrenergic neurotransmitters, protein kinase inhibitors, inflammation modulation, NMDA antagonism, biomarkers, and AI-assisted drug discovery.The second section explores natural alkaloidal and non-alkaloidal compounds, molecular docking, SAR analysis, and daily consumable resources, with the third section investigating marine-derived AChE inhibitors, dual- and multi-target drug concepts, and emerging therapeutic compounds. This book equips the scientific community with a robust foundation for understanding and innovating in Alzheimer's Disease therapy. By integrating molecular biology, pharmacology, and computational approaches, it empowers researchers and clinicians to address treatment challenges, optimize drug design, and leverage natural products for multifactorial intervention. - Explores cholinesterase inhibitors for cognitive improvement- Summarizes receptor mechanisms in cholinergic transmission- Reviews marine and plant-derived AChE inhibitors for innovative treatments- Presents emerging drug therapies and multitarget natural compounds for Alzheimer's Disease